Radiopharm announces 50% enrollment in Phase 2b trial of RAD101

Radiopharm (RADX) Theranostics announced that the Phase 2b trial evaluating RAD101 imaging in brain metastases has achieved 50% patient enrollment threshold. “Enrolling 50% of the patients in our Phase 2b study of RAD101 is a meaningful achievement for our RAD101 development program that brings us closer to demonstrating its clinical benefit in distinguishing between tumor recurrence and radiation necrosis in patients with brain metastasis following anticancer treatments, like SRS/radiation,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “Meeting this half-way milestone, along with our continuing momentum in patient enrollment, gives us further confidence in our plans to complete enrollment and share topline results in the first half of 2026.”